Clinical Trial Update: A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] [Phase 3]

View source ↗

Summary

Phase 3 long-term extension study of OPC-41061 in autosomal dominant polycystic kidney disease (ADPKD) completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• OPC-41061

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-07-27